National IVIG Reach AOM Infusion has a pharmacy license in all 50 states and a growing national footprint in intravenous immunoglobulin (IVIG) therapy, presenting a clear cross-sell opportunity for expanded product lines and partnerships with suppliers and manufacturers seeking reliable distribution across the U.S.

Strategic Partnerships Recent partnerships with Kedrion Biopharma and inclusion in Kedrion's limited distribution network for QIVIGY position AOM Infusion as a credible distribution and care integration partner for high-demand specialty immunoglobulin therapies, suggesting collaboration angles for additional Ig products and supply chain services.

Growth Financing Investments from Revelstoke Capital Partners indicate access to growth capital, enabling sales teams to pursue larger contracts, expand capabilities, and accelerate market reach with enterprise clients and health systems seeking scalable infusion services.

Expansion Footprint Expansion of offices, including a move to Industry City in New York, signals active market expansion and potential entry points for regional healthcare networks and hospital systems seeking regional infusion partnerships and centralized patient care coordination.

Clinical Expertise With a 30-year track record in infusion care for over 80 chronic conditions and a focus on IVIG and complex therapies, there is an opportunity to position AOM Infusion as a preferred partner for health systems prioritizing specialized therapy programs, patient outcomes, and integrated care teams.